Azathioprine Compared to Mycophenolate Mofetil Treatment in Patients with Interstitial Lung Disease Associated with Systemic Sclerosis

被引：0
|
作者：
Shell, J. [1 ]
Kapralik, J. [2 ]
Jones, A. [3 ]
Farooqi, M. [2 ]
Beattie, K. [4 ]
Kolb, M. R. [2 ]
Cox, G. P. [2 ]
Scallan, C. J. [5 ]
Larche, M. J. [4 ]
Khalidi, N. A. [4 ]
Hambly, N. [5 ]
机构：
[1] McMaster Univ, Dept Med, Hamilton, ON, Canada
[2] McMaster Univ, Div Respirol, Dept Med, Hamilton, ON, Canada
[3] McMaster Univ, Dept Hlth Res Methods, Hamilton, ON, Canada
[4] McMaster Univ, Div Rheumatol, Dept Med, Hamilton, ON, Canada
[5] McMaster Univ, Respirol, Hamilton, ON, Canada
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2021年 / 203卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A1915
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Effect Of Mycophenolate Mofetil On Scleroderma-Associated Interstitial Lung Disease
    Baqir, M.
    Makol, A.
    Osborn, T. G.
    Bartholmai, B.
    Ryu, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [32] PROGRESSIVE INTERSTITIAL LUNG DISEASE IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
    Cuomo, G.
    Di Vico, C.
    Perretta, D.
    Iandoli, C.
    Ciaburri, R.
    Adamo, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1657 - 1658
  • [33] The effect of nintedanib versus mycophenolate mofetil in the Fra2 mouse model of systemic sclerosis-associated interstitial lung disease
    Wollin, L.
    Trinh-Minh, T.
    Zhang, Y.
    Distler, J. H. W.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (04) : S134 - S141
  • [34] Treatment with mycophenolate mofetil is associated with improved nailfold vasculature in systemic sclerosis
    Wildt, Marie
    Andreasson, Kristofer
    Hamberg, Viggo
    Hesselstrand, Roger
    Wuttge, Dirk M.
    RHEUMATOLOGY, 2024, 63 (02) : 385 - 391
  • [35] Systemic Treatment of Pediatric Atopic Dermatitis with Azathioprine and Mycophenolate Mofetil
    Waxweiler, Weston T.
    Agans, Robert
    Morrell, Dean S.
    PEDIATRIC DERMATOLOGY, 2011, 28 (06) : 689 - 694
  • [36] Mycophenolate Versus Placebo for the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease
    Volkmann, Elizabeth R.
    Tashkin, Donald P.
    Li, Ning
    Roth, Michael
    Khanna, Dinesh
    Hoffmann-Vold, Anna-Maria
    Clements, Philip J.
    Furst, Daniel E.
    Elashoff, Robert
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [37] Mycophenolate Versus Placebo For The Treatment Of Systemic Sclerosis-Related Interstitial Lung Disease
    Tashkin, D. P.
    Volkmann, E.
    Roth, M. D.
    Li, N.
    Khanna, D.
    Furst, D.
    Elashoff, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [38] Efficacy of Mycophenolate As a Maintenance Therapy Following the Administration of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis
    Narvaez, Javier
    Borrell Panos, Helena
    Castellvi, Ivan
    Heredia, Sergi
    Millan, Milena
    Herrera, Susana
    Armengol, Eulalia
    Maria LLobet, Josep
    Miquel Nolla, Joan
    Molina, Maria
    Jose Alegre, Juan
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [39] Rituximab treatment in patients with systemic sclerosis and interstitial lung disease
    Mohammed, Abdel Gaffar A.
    Alshihre, Ammar
    Al-Homood, Ibrahim Abdulrazag
    ANNALS OF THORACIC MEDICINE, 2017, 12 (04) : 294 - 297
  • [40] Mycophenolate in Patients with Systemic Sclerosis-associated Interstitial Lung Disease: A Systematic Review and Meta-Analysis
    Herman, Derrick
    Ghazipura, Marya
    Barnes, Hayley
    Macrea, Madalina
    Knight, Shandra L.
    Silver, Richard M.
    Montesi, Sydney B.
    Raghu, Ganesh
    Hossain, Tanzib
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2024, 21 (01) : 136 - 150
12345